Pancreatic diseases and inflammatory bowel diseases: a random or regular combination?


Cite item

Full Text

Abstract

Pathology of the pancreas in inflammatory bowel disease (IBD) is more common than in the general population and includes a wide range of manifestations from asymptomatic to severe disorders. Acute pancreatitis, chronic pancreatitis, autoimmune pancreatitis, exocrine pancreatic insufficiency, increased pancreatic enzymes and structural duct anomalies are often associated with IBD. They can be either a manifestation of IBD itself or develop independently.

About the authors

V A Akhmedov

Omsk State Medical University

Email: v_akhmedov@mail.ru
д.м.н., проф., зав. каф. медицинской реабилитации ДПО ФГБОУ ВО «ОмГМУ» Минздрава России; ORCID: 0000-0002-7603-8481 Omsk, Russia

O V Gaus

Omsk State Medical University

к.м.н., ассистент каф. факультетской терапии, профессиональных болезней ФГБОУ ВО «ОмГМУ» Минздрава России, ORCID: 0000-0001-9370-4768 Omsk, Russia

References

  1. Vavricka S.R, Schoepfer A, Scharl M, Lakatos P.L, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi: 10.1097/MIB.0000000000000392
  2. Ramos L.R, Sachar D.B, Di Maio C.J, Colombel J.F, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95-104. doi: 10.1093/ecco-jcc/jjv153
  3. Spanier B.W, Dijkgraaf M.G, Bruno M.J. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007
  4. Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert J.P, Perez-Calle J.L, Vera I, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine - induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623-8. doi: 10.1111/j.1365-2036.2008.03746.x.
  5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17(4):286-91.
  6. Rasmussen H.H, Fonager K, Sorensen H.T, Pedersen L, Dahlerup J.F, Steffensen F.H. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow - up study. Scand J Gastroenterol. 1999;34(2):199-201.
  7. Chen Y.T, Su J.S, Tseng C.W, Chen C.C, Lin C.L, Kao C.H. Inflammatory bowel disease on the risk of acute pancreatitis: A population - based cohort study. J Gastroenterol Hepatol. 2016;31(4):782-7. doi: 10.1111/ jgh.13171
  8. Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52(6):714-7. doi: 10.1097/MPG. 0b013e3182065cad
  9. Moolsintong P, Loftus E.V. Jr, Chari S.T, Egan L.J, Tremaine W.J, Sandborn W.J. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080-4. doi: 10.1097/01
  10. Pajares J.A, Hernandez L, Menchen P, Menchen L. Duodenopancreatic fistula complicating upper gastrointestinal Crohn's disease: successful treatment with infliximab. Am J Gastroenterol. 2009;104(7):1863-4. doi: 10.1038/ajg.2009.180
  11. Goldin E, Libson E, Wengrower D, Antal S, Kovacs Z, Rachmilewitz D. Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis: treatment by endoscopic insertion of a biliary stent. Int Surg. 1990;75(1):58-60.
  12. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48(4):598-605. doi: 10.1016/j.jhep.2007.11.019
  13. Srinath A.I, Gupta N, Husain S.Z. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):465-75. doi: 10.1097/MIB.0000000000000611
  14. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53(4):542-8. doi: 10.1136/gut.2003.025411
  15. Zhang F.M, Xu C.F, Shan G.D, Chen H.T, Xu G.Q. Is gallstone disease associated with inflammatory bowel diseases? A meta - analysis. J Dig Dis. 2015;16(11):634-41. doi: 10.1111/1751-2980.12286
  16. Fagagnini S, Heinrich H, Rossel J.B, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One. 2017;12(10):e0185193. doi: 10.1371/journal.pone.0185193
  17. Jeong Y.H, Kim K.O, Lee H.C, Sohn S.H, Lee J.W, Lee S.H, et al. Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. Medicine (Baltimore). 2017;96(31):e7653. doi: 10.1097/MD.0000000000007653
  18. Faintuch J, Mott C.B, Machado M.C. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70(3):271-2.
  19. Ransford R.A, Langman M.J. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-9. doi: 10.1136/gut.51.4.536
  20. Russo L, Schneider G, Gardiner M.H, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol. 2014;70(6):709-17. doi: 10.1007/s00228-014-1660-7
  21. Isaacs K.L, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12(2):198-9.
  22. Stobaugh D.J, Deepak P. Effect of tumor necrosis factor - alpha inhibitors on drug - induced pancreatitis in inflammatory bowel disease. Ann Pharmacother. 2014;48(10):1282-7. doi: 10.1177/1060028014540869
  23. Triantafillidis J.K, Cheracakis P, Hereti I.A, Argyros N, Karra E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol. 2000;95(11):3334-6.
  24. Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-Induced Pancreatitis: Is There Underrecognition? A Case Report and SystematicReview of the Literature. Case Rep Gastrointest Med. 2019;2019:4840539. doi: 10.1155/2019/4840539
  25. O'Halloran E, Hogan A, Mealy K. Metronidazole - induced pancreatitis. HPB Surg. 2010;2010:523468. doi: 10.1155/2010/523468
  26. Tsesmeli N.E, Giannoulis K.E, Savopoulos C.G, Vretou E.E, Ekonomou I.A, Giannoulis E.K. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19(9):805-6.
  27. Sadr-Azodi O, Mattsson F, Bexlius T.S, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population - based nested case - control study. JAMA Int Med. 2013;173(6):444-9. doi: 10.1001/jamainternmed.2013.2737
  28. Dong L.H, Liu Z.M, Wang S.J, Zhao S.J, Zhang D, Chen Y, Wang Y.S. Corticosteroid therapy for severe acute pancreatitis: a meta - analysis of randomized, controlled trials. Int J Clin Exp Pathol. 2015;8(7):7654-60.
  29. Tenner S, Baillie J, De Witt J, Vege S.S, American College of G. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15;1416. doi: 10.1038/ajg.2013. 218
  30. Nesvaderani M, Eslick G.D, Cox M.R. Acute pancreatitis: update on management. Med J Aust. 2015;202(8):420-3.
  31. Охлобыстин А.В. Трудно ли диагностировать аутоиммунный панкреатит? Современные представления, подходы к лечению и исходы. Русский медицинский журнал. 2015;21:1281-6.
  32. Tsen A, Alishahi Y, Rosenkranz L. Autoimmune pancreatitis and inflammatory bowel disease: an updated review. J Clin Gastroenterol. 2017;51(3):208-14. doi: 10.1097/MCG.0000000000000737
  33. Kamisawa T, Chari S.T, Giday S.A, Kim M.H, Chung J.B, Lee K.T, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809-14. doi: 10.1097/MPA.0b013e3182258a15
  34. Ueki T, Kawamoto K, Otsuka Y, Minoda R, Maruo T, Matsumura K, et al. Prevalence and clinico - pathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas. 2015;44(3):434-40. doi: 10.1097/MPA.000000000000026
  35. Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol. 2018;53(4):475-83. doi: 10.1007/s00535-018-1440-8
  36. Lorenzo D, Maire F, Stefanescu C, Gornet J.M, Seksik P, Serrero M, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033
  37. Ravi K, Chari S.T, Vege S.S, Sandborn W.J, Smyrk T.C, Loftus E.V, Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15(9):1326-30. doi: 10.1002/ibd.20898
  38. Smyk D.S, Rigopoulou E.I, Koutsoumpas A.L, Kriese S, Burroughs A.K, Bogdanos D.P. Autoantibodies in autoimmune pancreatitis. Int J Rheumatol. 2012;2012:940831. doi: 10.1155/2012/940831
  39. Ахмедов В.А., Гаус О.В. Современные взгляды на механизмы формирования и перспективы купирования болевого абдоминального синдрома у пациентов хроническим панкреатитом. Экспериментальная и клиническая гастроэнтерология. 2016;134(10):99-103.
  40. Хатьков И.Е., Маев И.В., Абдулхаков С.Р., Алексеенко С.А., Алиева Э.И., Алиханов Р.Б. и др. Российский консенсус по диагностике и лечению хронического панкреатита. Терапевтический архив. 2017;89(2):105-13. doi: 10.17116/ terarkh20178 921 05-113
  41. Ахмедов В.А., Гаус О.В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017;89(1):128-33. doi: 10.17116/terarkh2017891128-133
  42. Rana S.S, Vilmann P. Endoscopic ultrasound features of chronic pancreatitis: A pictorial review. Endosc Ultrasound. 2015;4(1):10-4. doi: 10.4103/2303-9027.151314
  43. Barthet M, Hastier P, Bernard J.P, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141-8.
  44. Chen Y.L, Hsu C.W, Cheng C.C, Yiang G.T, Lin C.S, Lin C.L, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population - based cohort study. Curr Med Res Opin. 2017;33(6):1077-82. doi: 10.1080/03007995.2017.1300143
  45. Хатьков И.Е., Маев И.В., Бордин Д.С., Кучерявый Ю.А., Абдулхаков С.Р., Алексеенко С.А. и др. Российский консенсус по диагностике и лечению хронического панкреатита: заместительная ферментная терапия. Терапевтический архив. 2017;89(8):80-7. doi: 10.17116/terarkh 201789880-87
  46. Maconi G, Dominici R, Molteni M, Ardizzone S, Bosani M, Ferrara E, et al. Prevalence of pancreatic in sufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53(1):262-70. doi: 10.1007/s10620-007-9852-y
  47. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3(2-3):185-93.
  48. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31(5):517-23.
  49. Soubieres A.A, Poullis A. Emerging role of novel bio - markers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. doi: 10.4292/ wjgpt.v7.i1.41
  50. Bogdanos D.P, Rigopoulou E.I, Smyk D.S, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific - pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143-8. doi: 10.1016/j.autrev.2011.09.00
  51. Bogdanos D.P, Roggenbuck D, Reinhold D, Wex T, Pav lidis P, von Arnim U, et al. Pancreatic - specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012;12:102. doi: 10.1186/1471-230X-12-102
  52. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou M.G, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. doi: 10.1155/2012/64083
  53. Gross S, Bakker S.F, van Bodegraven A.A, van Hoogstraten I.M, Gelderman K.A, Bouma G, et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014;23(2):127-33. doi: 10.15403/jgld.2014.1121.232.sg1
  54. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018;8(1):399. doi: 10.1038/s41598-017-18622-1
  55. Парфенов А.И., Быкова С.В., Сабельникова Е.А., Маев И.В., Баранов А.А., Бакулин И.Г. и др. Всероссийский консенсус по диагностике и лечению целиакии у детей и взрослых. Терапевтический архив. 2017;89(3):94-107. doi: 10.17116/terarkh20 1789394-107
  56. Fotios S Fousekis, Vasileios I Theopistos, Konstantinos H Katsanos, Dimitrios K Christodoulou. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-51. doi: 10.14740/jocmr3561w
  57. Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005;11(10):903-8. doi: 10.1097/01.mib.0000183419.17563.17

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies